Improvement of Anemia in Hemodialysis Patients Treated by Hemodiafiltration with High-Volume On-Line-Prepared Substitution Fluid

Background: Hemodiafiltration (HDF) is associated with a lower incidence of neuropathy, carpal tunnel syndrome, joint pain, and partial correction of anemia. HDF with on-line-prepared substitution fluid (OL HDF), as compared with conventional hemodialysis, increases the treatment tolerance and, as compared with standard HDF, avoids storage problems and allows a higher substitution volume at low cost. Methods: Thirty-two hemodialysis patients treated by OL HDF for at least 9 months were studied. Hemoglobin, hematocrit, iron metabolism, serum albumin, dialysis dose and dry body weight were determined under a settled condition with regular hemodialysis 3 months before the transfer to OL HDF. The same parameters were analyzed 3, 6 and 9 months after the beginning of the new treatment modality. Results: During OL HDF, hemoglobin values significantly increased in patients without addition of recombinant human erythropoietin (rHuEPO): baseline vs. 6 months 11 ± 1.7 vs. 12 ± 1.8 g/dl (p < 0.01); baseline vs. 9 months 11 ± 1.7 vs. 12 ± 1.6 g/dl (p < 0.05). In patients on a maintenance dose of rhuEPO, this could be significantly reduced, while the target hemoglobin levels were maintained (10.6 ± 0.9 g/dl): baseline 99.8 ± 50.4 U/kg/week, 3rd month 76.2 ± 43 U/kg/week, 6th month 64.3 ± 37 U/kg/week, and 9th month 59.4 ± 38.6 U/kg/week (p = 0.007, p = 0.0006, and p = 0.0007, respectively, vs. baseline). Iron metabolism, dialysis dose, dry body weight and serum albumin levels did not significantly change during the follow-up period. Further, a stability of the rHuEPO supplementation was observed in 14 patients followed up for 24 months. Conclusions: OL HDF influences anemia and rHuEPO dose. It allows considerable anemia correction in patients without rHuEPO treatment, while it significantly reduces rHuEPO doses in those on rHuEPO treatment as compared with standard hemodialysis. The rHuEPO costs are consequently reduced.

[1]  T. Drüeke.  Beta2-microglobulin and amyloidosis. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  A. Baj,et al.  Plasma or whole blood concentrations of trace elements in patients treated by haemodiafiltration with on-line prepared substitution fluid. , 1998, Nephrology, Dialysis and Transplantation.

[3]  E. Friedman,et al.  The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. , 1996, The New England journal of medicine.

[4]  A. Baj,et al.  Trace elements and micropollutant anions in the dialysis and reinfusion fluid prepared on-line for haemodiafiltration. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  T. Drüeke.  β2‐Microglobulin and amyloidosis , 2000 .

[6]  À. Argilés,et al.  On-line haemodiafiltration. Safety and efficacy in long-term clinical practice. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  A. Levin,et al.  Evidence-based recommendations for the clinical use of recombinant human erythropoietin. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  B. Canaud,et al.  Microbiologic Purity of Dialysate:Rationale and Te chnical Aspects , 2000, Blood Purification.

[9]  G. Panzetta,et al.  Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy: a cross-over multicentric study. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  S. Massry,et al.  Effect of parathyroid hormone on erythropoiesis. , 1981, The Journal of clinical investigation.

[11]  K. Eckardt.  Anaemia correction--does the mode of dialysis matter? , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  R. McGonigle,et al.  Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. , 1984, Kidney international.

[13]  J. Rácek,et al.  The Effect of Hemodialysis and Acetate-Free Biofiltration on Anemia , 2000, The International journal of artificial organs.

[14]  P. Watson,et al.  Total body water volumes for adult males and females estimated from simple anthropometric measurements. , 1980, The American journal of clinical nutrition.

[15]  M. Gonella,et al.  Improvement of anemia in patients on chronic dialysis treated by hemodiafiltration. , 1989, Blood purification.

[16]  W Samtleben,et al.  A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. , 2000, Journal of the American Society of Nephrology : JASN.

[17]  Jürgen Floege,et al.  β2-Microglobulin–derived amyloidosis: An update , 2001 .

[18]  G. Kaysen.  The microinflammatory state in uremia: causes and potential consequences. , 2001, Journal of the American Society of Nephrology : JASN.

[19]  S. Mandolfo,et al.  Effect of hemodialysis and hemodiafiltration on uremic neuropathy. , 1991, Blood purification.

[20]  K. Leunissen,et al.  Fluid state and blood pressure control in patients treated with long and short haemodialysis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  V. Wizemann,et al.  On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  F. Maduell,et al.  Change from conventional haemodiafiltration to on-line haemodiafiltration. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  J. Adamson,et al.  Disorders of red blood cell production in uremia. , 1970, Archives of internal medicine.

[24]  C. Tetta,et al.  Convective treatments with on-line production of replacement fluid: a clinical experience lasting 6 years. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  F. Locatelli,et al.  Effect of high-flux dialysis on the anaemia of haemodialysis patients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  À. Argilés,et al.  Comparison of hemodialysis and hemodiafiltration: a long-term longitudinal study. , 1992, Kidney international.

[27]  J A Sargent,et al.  Mathematic modeling of dialysis therapy. , 1980, Kidney international. Supplement.

[28]  E. Paganini,et al.  The use of iron in patients on chronic dialysis: mistake and misconceptions. , 1998, Journal of nephrology.